Despite setbacks with ANX007 in Geographic Atrophy, the FDA approved a phase ... where the body’s antibodies mistakenly attack the peripheral nerves, causing muscle weakness and, in severe ...

UK, Cambridge-based Quethera runs an ophthalmic gene therapy programme, which uses a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into retinal cells to ...

“By demonstrating the potential of sustained drug delivery to support retinal neurons, this device could pave the way for future treatments targeting other neurodegenerative retinal conditions, such ...

As OCT technology quickly evolves to more portable units with higher resolution and the capacity to image more peripheral ... serous retinal detachment and, therefore, potential for visual function, ...

Identifying a peripheral biomarker that reliably tracks ... eMTBR-tau243 also had the strongest associations with brain atrophy, early cognitive decline, and global cognitive scores in individuals ...

The current state of treatment for geographic atrophy is marked by two approved ... despite their vitreous and retina looking essentially normal. Vitreous floaters are a common ocular condition ...

Centers such as the Institute for Saint John's Health Center in California, Byers Eye Institute, McPherson Eye Research Institute, Retina specialist at Providence Saint John's Health Center ...

His clinical interests include cerebral palsy, muscular dystrophies, spinal muscular atrophy, peripheral neuropathies, and other neuromuscular conditions (including spine). His research interests are ...

Astellas confirmed today that it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy (GA), based on feedback from the EU regulator. It is a major ...

Note the bullous nature of the retinal detachment, along with the corrugated appearance of the subretinal fluid. Diagram showing multiple peripheral retinal tears and holes, more typically seen in ...